What is the appropriate management for a bleeding, fungating breast tumor complicated by maggot (myiasis) infestation?

Management of Bleeding Fungating Breast Mass with Myiasis

Immediate mechanical removal of all maggots combined with systemic triple therapy (ivermectin 12 mg daily for 3 days, albendazole 400 mg twice daily for 3 days, and clindamycin 300 mg three times daily for 5 days) is the most effective approach for wound myiasis, followed by appropriate wound care and systemic cancer treatment. 1

Immediate Myiasis Management

Maggot Removal and Systemic Treatment

• Physically extract all visible maggots from the wound using forceps or irrigation, as mechanical removal remains the cornerstone of initial management 2, 3
• Administer triple therapy immediately: ivermectin 12 mg orally daily for 3 days, albendazole 400 mg orally twice daily for 3 days, and clindamycin 300 mg orally three times daily for 5 days 1
  • This regimen achieves 73% reduction in maggot burden by day 1 and 93% reduction by day 3 1
  • Side effects are self-limiting and well-tolerated 1
• Apply topical turpentine oil dressings to the wound after mechanical debridement 1

Pain and Symptom Control

• Initiate oral morphine titrated to pain scores, as patients typically require substantial analgesia (mean dose 100 mg in clinical studies) 1
• Monitor for associated symptoms including wound odor, exudate, bleeding, and psychological distress 1, 4

Wound Care for Fungating Breast Lesions

Local Wound Management

• Select dressings based on specific wound characteristics: use absorbent dressings for exudative wounds, antimicrobial dressings for infected tissue, and odor-controlling dressings (charcoal-based) for malodorous wounds 5
• Maintain clean wound environment with regular dressing changes to prevent re-infestation 5
• Address psychosocial complications proactively, as fungating wounds significantly impact quality of life and body image 5, 4

Systemic Cancer Treatment

Treatment Approach for Stage IV Disease with Intact Primary

• Prioritize systemic therapy over immediate surgery for metastatic breast cancer with fungating primary tumor 6
• Consider surgery or radiation therapy specifically for palliation of symptoms including bleeding, fungation, and pain—but only after initial systemic treatment and if complete local clearance is achievable 6
• Ensure multidisciplinary involvement including breast surgery and reconstructive surgery if surgical intervention is pursued 6

Evidence on Primary Tumor Resection

• Two prospective randomized trials showed no survival benefit from primary tumor resection in de novo metastatic breast cancer (OS 19.2 vs 20.5 months, HR 1.04) 6
• Surgery should be reserved for patients requiring palliation of local complications when other disease sites are not immediately life-threatening 6

Ongoing Management

Supportive Care Framework

• Provide appropriate psychosocial, supportive, and symptom-related interventions from the time of metastatic diagnosis as routine care 7
• Monitor patients every 2-4 months if on endocrine therapy, or before each chemotherapy cycle 7
• Ensure lifelong access to effective palliative care services 7

Common Pitfalls to Avoid

• Delayed treatment seeking worsens prognosis for both myiasis and underlying malignancy—patients in case reports waited 10 days before seeking care, negatively impacting outcomes 3
• Do not rely solely on mechanical removal without systemic therapy, as this approach is less effective 1
• Avoid pursuing aggressive surgical resection in metastatic disease without clear palliative indication, as evidence does not support survival benefit 6

Treatment Selection Based on Tumor Biology

• Base systemic therapy choice on hormone receptor status, HER2 status, tumor burden, and patient performance status 6, 7
• Endocrine therapy is preferred for hormone receptor-positive disease unless rapid response is needed 7
• HER2-directed therapy should be offered early to all HER2-positive patients 7